IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

29. November 09:29 Valneva, Moderna & Co: Impfstoff-Aktien kräftig im Plus – neue ...

29. November 09:33 Deutsche Bank: Abverkauf – positive Nachricht geht völlig unter

29. November 10:00 Axon: Die volle Ladung

29. November 10:07 Letzte Chance: Nvidia und Bitcoin im Metaverse. Verdopplung bis 2025

29. November 10:07 Thyssenkrupp: Das wird der Gamechanger

MS Industrie AG

Original-Research: MS Industrie AG (von Montega AG): Kaufen

29. November 2021